‘Bespoke’ mRNA vaccine significantly reduces risk of melanoma recurrence or death, clinical trial shows
Reported bythe Guardian ↗·Sourced by Goodlede
A phase III clinical trial of 1,137 melanoma patients found that the personalised mRNA vaccine intismeran combined with pembrolizumab reduced the risk of cancer recurrence or death by 42% compared with pembrolizumab alone at two years post-treatment.
The trial involved patients whose melanoma had been surgically removed. Availability and cost outside Australia remain unclear.
Goodlede runs a two-pass source check on every story: one pass finds it, a second skeptical pass re-verifies the claim and writes what it doesn’t prove. This is a source check, not an independent fact-check — confirm anything important at the link above.
Read the full story at the Guardian
Read original story ↗More good news, verified daily.
Goodlede covers positive developments across science, nature, rights, and human achievement — verified before they appear. No hype, no roundups, no PR wires.
© 2026 Wag Media, LLC
More from Goodlede
Kindness
NYC to offer free pet food at 22 pantries across all five boroughs
ABC7 New York · Verified
Human Feats
This Nova Scotian just ran his first marathon. He trained for it by eating donairs
CBC Canada · Verified
Kindness
Kaedyn's Krusade: Glendale school rallies around fourth-grade student who needs bone marrow transplant
ABC15 Arizona · Verified